Cartherics is currently undertaking a new capital raise to initiate clinical trials for its lead allogeneic cell therapy for ovarian cancer. CTH-401 is the only NK cell product currently under development that targets the adenocarcinoma specific antigen – TAG-72.
The company is looking to raise up to AU$20 million to support its ongoing development activities and complete all activities in preparation for clinical trials planned for 2025. The financing will also allow Cartherics to advance its earlier stage projects and fund its ongoing operations through to 2026.
Read more in the Australian Financial Review here: Rearming the body to fight cancer